William Blair Comments on Illumina, Inc.’s FY2017 Earnings (ILMN)
Illumina, Inc. (NASDAQ:ILMN) – Analysts at William Blair raised their FY2017 earnings per share (EPS) estimates for shares of Illumina in a report released on Monday. William Blair analyst A. Murphy now anticipates that the life sciences company will post earnings per share of $3.73 for the year, up from their previous forecast of $3.62. William Blair also issued estimates for Illumina’s Q3 2018 earnings at $1.19 EPS.
Several other analysts have also recently commented on ILMN. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, August 9th. Vetr upgraded Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price on the stock in a report on Wednesday, August 9th. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Cowen and Company reiterated an “outperform” rating and issued a $200.00 target price on shares of Illumina in a report on Wednesday, August 2nd. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $200.00 target price on shares of Illumina in a report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. Illumina currently has a consensus rating of “Hold” and a consensus price target of $200.88.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/21/william-blair-comments-on-illumina-inc-s-fy2017-earnings-ilmn.html.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the prior year, the business posted $0.97 earnings per share. The firm’s revenue was up 17.6% on a year-over-year basis.
A number of large investors have recently made changes to their positions in the business. First Citizens Bank & Trust Co. grew its stake in Illumina by 0.4% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 12 shares during the period. Puzo Michael J grew its stake in Illumina by 0.4% in the 2nd quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after purchasing an additional 25 shares during the period. Flagship Harbor Advisors LLC grew its stake in Illumina by 1.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after purchasing an additional 35 shares during the period. Broderick Brian C grew its stake in Illumina by 0.3% in the 2nd quarter. Broderick Brian C now owns 13,152 shares of the life sciences company’s stock valued at $2,282,000 after purchasing an additional 40 shares during the period. Finally, Nordea Investment Management AB grew its stake in Illumina by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 6,798 shares of the life sciences company’s stock valued at $1,180,000 after purchasing an additional 42 shares during the period. Hedge funds and other institutional investors own 90.76% of the company’s stock.
In related news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total value of $4,222,200.00. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $113,825,445.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the completion of the sale, the senior vice president now directly owns 24,908 shares of the company’s stock, valued at $5,263,807.64. The disclosure for this sale can be found here. Insiders sold a total of 172,446 shares of company stock valued at $35,486,114 over the last three months. 0.89% of the stock is currently owned by insiders.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.